How urine copper changes over the day in Wilson disease
Studies daily urine copper patterns in people with Wilson disease.
Key facts
- Who runs it
- Hospices Civils de Lyon
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients
- Status
- Recruiting
- People taking part
- 30 people, planned
- Started
- 10 Jan 2025
- Expected to end
- 10 Feb 2027
- Type of study
- Observational, 3 groups
- Treatments tested
- urine and blood test
- Record updated
- 15 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with Wilson disease who take D-Pencillamine, Trientine or Zinc. It studies which time of day urine copper levels most closely reflect a full 24-hour urine collection.
- Age
- 6 years to 70 years
- Sex
- All sexes
- Disease stage
- Confirmed Wilson disease (Leipzig score ˃4).
- Earlier treatment
- Must currently take D-Pencillamine, Trientine or Zinc. No change in treatment within the last 6 months.
Main reasons for not taking part
- Change in treatment within the last 6 months
- Past liver transplant
- Known long-term kidney failure (GFR < 30 ml/min)
- Long-term use of diuretics (water pills) or corticosteroids
- Not able to collect urine over 24 hours
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4)
- Age ≥ 6 years and ≤70 years
- Patient able to perform 24h urine
- Current treatment with D-Pencillamine, Trientine or Zinc
- Non-opposition of patient and/or legal representatives for minor patients
Who cannot take part
- Patients who had a change in treatment within the last 6 months before the inclusion
- Patients who have undergone liver transplantation
- Patients on long-term diuretic or corticosteroid therapy
- Patients with known chronic renal failure (GFR < 30 ml/min)
- Persons deprived of liberty by a judicial or administrative decision
- Patient under judicial protection, unable to express consent
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 6 and 70 years old?
This trial is currently available in France.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Wilson's disease (WD) is a genetic disorder characterized by an accumulation of copper in the body, mainly in the liver and brain. Patients suffering from this disease are monitored by liver function tests, blood copper levels, and 24-hour urinary copper determinations.
Read full original descriptionShow less
Treatment is based either on chelating the copper accumulated in the body using D-penicillamine or Trientine or on limiting intestinal copper absorption with zinc salts.
Monitoring copper elimination in urine collected over 24 hours is essential for estimating a patient's copper load, adapting treatment dosage, and detecting any copper deficiency.
Nevertheless, urine collection is often complicated for patients, given the obvious constraints of collecting urine over 24 hours. Without this, clinical decisions are usually made based on spot urine.
There is no official recommendation for monitoring urinary copper elimination other than on 24-hour urine.
According to studies on healthy volunteers under physiological conditions, urinary copper elimination occurs according to a circadian rhythm, with minimal copper elimination between 8 pm and 4 am and maximum between 8 am and noon.
The study would aim to find the period of the day best correlated with 24h urinary copper excretion
The 3 groups in the trial
- Group 1 - DP
Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4 ). Aged between 6 years and 70 years. Treated with D-Pencillamine
Treatment: urine and blood test
- Group 2 - Trientine
Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4 ). Aged between 6 years and 70 years. Treated with Trientine
Treatment: urine and blood test
- Group 3 - ZINC
Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4 ). Aged between 6 years and 70 years. Treated with Zinc.
Treatment: urine and blood test
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients Treated With Chelators or Zinc Salts
- Plain-language title
- How urine copper changes over the day in Wilson diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06430359, who can take part
- Record updated
- 15 January 2026